1832 Asset Management’s Core Laboratories CLB Stock Holding History

1832 Asset Management’s Portfolio CLB Stock Details CLB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-652	Closed	-$13.2K	–	721
2024 Q2	$13.2K	Hold	652	–	–	﹤0.01%	750
2024 Q1	$11.1K	Hold	652	–	–	﹤0.01%	754
2023 Q4	$11.5K	Sell	652 -30	-4%	-$604	﹤0.01%	741
2023 Q3	$16.4K	Hold	682	–	–	﹤0.01%	735
2023 Q2	$15.9K	Hold	682	–	–	﹤0.01%	740
2023 Q1	$15K	Hold	682	–	–	﹤0.01%	778
2022 Q4	$13.8K	Hold	682	–	–	﹤0.01%	806
2022 Q3	$9K	Hold	682	–	–	﹤0.01%	801
2022 Q2	$14K	Hold	682	–	–	﹤0.01%	793
2022 Q1	$21K	Buy	+682	New	+$19.1K	﹤0.01%	837
2017 Q2	–	Sell	-5,500	Closed	-$637K	–	670
2017 Q1	$637K	Buy	+5,500	New	+$639K	﹤0.01%	482
2014 Q2	–	Sell	-39,000	Closed	-$7.79M	–	617
2014 Q1	$7.79M	Buy	+39,000	New	+$7.36M	0.03%	310

Other funds holding CLB

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $5.91B AUM 53.97% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

1832 Asset Management's CLB Position: Q3 2024 in Review

1832 Asset Management sold out of Core Laboratories (CLB) in Q3 2024, closing a stake of 652 shares — an estimated $13.2K sold.

1832 Asset Management first reported a position in CLB in Q1 2014 and held it in 12 quarters. The position peaked at $7.79M in Q1 2014. 191 funds tracked by Wall St. Rank hold CLB as of Q3 2024.

1832 Asset Management reported no remaining Core Laboratories position as of Q3 2024 after selling out during the quarter.
1832 Asset Management sold 652 Core Laboratories shares in Q3 2024, an estimated $13.2K.
1832 Asset Management first reported a position in Core Laboratories in Q1 2014 and held it in 12 quarters.
1832 Asset Management's Core Laboratories position peaked at $7.79M in Q1 2014.
191 funds tracked by Wall St. Rank held Core Laboratories as of Q3 2024.

Based on 1832 Asset Management's 13F filing for Q3 2024, filed 13 Nov 2024.